Morgan Stanley is upgraded to "buy on weakness" due to robust ROTCE targets and accelerating earnings momentum. MS delivered strong Q4 2025 results, with net interest income up double digits and ROTCE reaching 21.6%. The Series E preferred shares offer a 7.125% yield, and remain well covered, but carry elevated call risk if rates fall.









